Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Leukemia, Myeloid, Chronic-Phase 34Leukemia 30Leukemia, Myeloid, Acute 18Breast Neoplasms 18Recurrence 15Prostatic Neoplasms 14Leukemia, Lymphocytic, Chronic, B-Cell 13Neoplasm Metastasis 12Blast Crisis 12Multiple Myeloma 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 11Pancreatic Neoplasms 10Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Lung Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 7Glioblastoma 7Melanoma 6Lymphoma 6Glioma 6Rectal Neoplasms 5Philadelphia Chromosome 5Ovarian Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Hematologic Neoplasms 5

Interventions

Cyclophosphamide 14Dexamethasone 13Vincristine 11Cytarabine 11Methotrexate 9venetoclax 7Inotuzumab Ozogamicin 7Doxorubicin 7pegaspargase 6merphos 6blinatumomab 6Prednisone 6dexamethasone acetate 5dexamethasone 21-phosphate 5Mercaptopurine 5Calcium Dobesilate 5prednylidene 4deltacortene 4azathiopurine 4auricularum 4Specimen Handling 4Leucovorin 4Asparaginase 4Thioguanine 3Rituximab 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3fludarabine 2calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Dasatinib × Clear all
NCT05751044 2025-09-16

HEM-iSMART B

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Recruiting
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡